These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 20800650)
1. Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells. Dong L; Qi N; Ge RM; Cao CL; Lan F; Shen L Neurosci Lett; 2010 Nov; 484(3):210-4. PubMed ID: 20800650 [TBL] [Abstract][Full Text] [Related]
2. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Tabu K; Kimura T; Sasai K; Wang L; Bizen N; Nishihara H; Taga T; Tanaka S Mol Cancer; 2010 Feb; 9():39. PubMed ID: 20167130 [TBL] [Abstract][Full Text] [Related]
3. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174 [TBL] [Abstract][Full Text] [Related]
4. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling. Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372 [TBL] [Abstract][Full Text] [Related]
5. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122 [TBL] [Abstract][Full Text] [Related]
6. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311 [TBL] [Abstract][Full Text] [Related]
7. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Suetsugu A; Nagaki M; Aoki H; Motohashi T; Kunisada T; Moriwaki H Biochem Biophys Res Commun; 2006 Dec; 351(4):820-4. PubMed ID: 17097610 [TBL] [Abstract][Full Text] [Related]
8. Expression and regulation of AC133 and CD133 in glioblastoma. Campos B; Zeng L; Daotrong PH; Eckstein V; Unterberg A; Mairbäurl H; Herold-Mende C Glia; 2011 Dec; 59(12):1974-86. PubMed ID: 21901757 [TBL] [Abstract][Full Text] [Related]
9. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043 [TBL] [Abstract][Full Text] [Related]
10. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568 [TBL] [Abstract][Full Text] [Related]
11. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564 [TBL] [Abstract][Full Text] [Related]
12. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620 [TBL] [Abstract][Full Text] [Related]
13. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Yao J; Zhang T; Ren J; Yu M; Wu G Oncol Rep; 2009 Oct; 22(4):781-7. PubMed ID: 19724856 [TBL] [Abstract][Full Text] [Related]
14. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Ropolo M; Daga A; Griffero F; Foresta M; Casartelli G; Zunino A; Poggi A; Cappelli E; Zona G; Spaziante R; Corte G; Frosina G Mol Cancer Res; 2009 Mar; 7(3):383-92. PubMed ID: 19276180 [TBL] [Abstract][Full Text] [Related]
16. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338 [TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance genes in normal and cancer stem cells. Shervington A; Lu C Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776 [TBL] [Abstract][Full Text] [Related]
18. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Ding W; Mouzaki M; You H; Laird JC; Mato J; Lu SC; Rountree CB Hepatology; 2009 Apr; 49(4):1277-86. PubMed ID: 19115422 [TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455 [TBL] [Abstract][Full Text] [Related]
20. ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells. Cong ZX; Wang HD; Wang JW; Zhou Y; Pan H; Zhang DD; Zhu L Oncol Rep; 2013 Aug; 30(2):715-22. PubMed ID: 23708697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]